Chemotherapy's Role In Driving The Growth Of Xerostomia Therapeutics Market: A Key Catalyst Accelerating Xerostomia Therapeutics Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Xerostomia Therapeutics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for xerostomia therapeutics has been on a steady upward trend in the past few years. The market, which was valued at $2.14 billion in 2024, is anticipated to reach $2.24 billion in 2025, marking a compound annual growth rate (CAGR) of 4.7%. The surge during this historical period is mainly due to the rise in occurrence of xerostomia among the aged, ongoing development and research towards creating more effective products for xerostomia, an increase in awareness regarding products related to xerostomia, escalating number of medical conditions, and the growing prevalence of chronic diseases.

Xerostomia Therapeutics Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the xerostomia therapeutics market size is predicted to experience steady growth, escalating to $2.69 billion by 2029 with a compound annual growth rate (CAGR) of 4.7%. The uptrend during the forecast period could be due to ease of access to affordable drugs in the market, a higher incidence of oral health conditions, increased awareness among medical practitioners, government support, and an uptick in the use of medication. The forecast period will witness major trends such as the rise of artificial saliva and saliva substitutes, breakthroughs in technology and product innovations, personalized and targeted therapies, telehealth and remote patient monitoring, along with the emergence of non-invasive therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

What Are the Drivers Transforming the Xerostomia Therapeutics Market?
The growing utilization of chemotherapy for treating cancer is set to fuel the expansion of the xerostomia therapeutics market. Chemotherapy, a potent drug-based treatment methodology, is designed to obliterate or hinder the development of cancer cells. This rising endorsement of chemotherapy is primarily attributable to its proficiency in precisely targeting and eliminating malignant cells in the body. Xerostomia therapeutics encompass saliva-inducing medicines or mouthwashes that amplify saliva production and enhance flavor discernment, thereby facilitating patients' ability to eat and maintain wholesome nutrition. According to the National Cancer Institute in January 2022, a government organization based out of the US, estimated that cancer survivors in the country numbered 18.1 million, or 5.4% of the total populace. By 2032, it's projected that worldwide cancer survivors will reach 22.5 million - a 24.4% rise from current figures. Consequently, the escalating uptake of chemotherapy for cancer treatment is fostering growth in the xerostomia therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

What Are the Key Trends Driving Xerostomia Therapeutics Market Growth?
Top pharmaceutical companies functioning in the xerostomia therapeutics market are innovating non-obtrusive, patient-friendly treatments like oral sprays to meet the appeal for efficient and handy solutions for managing dry mouth. These sprays ensure precise targeting to the affected regions in the mouth, supplying adequate hydration and lubrication just where required. For example, K Pharmaceuticals, a pharmaceutical company hailing from India, introduced Aquoral in July 2023; it's a clinically-tested oral spray designed to offer relief from xerostomia, otherwise known as dry mouth. This condition, which can be triggered by various causes, including medication and diseases, can create discomfort, chewing and swallowing difficulties, along with oral health issues. Aquoral provides lasting relief for up to six hours by creating a durable protective shield across the mouth, reducing moisture evaporation and increasing comfort. In contrast to traditional aqueous-based treatments that need regular reapplication, Aquoral incorporates patented Oxidized Glycerol Triesters (OGT), a plant-originated, lipid-based technology that provides superior protection.

Which Segments in the Xerostomia Therapeutics Market Offer the Most Profit Potential?
The xerostomia therapeutics market covered in this report is segmented -

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric

Subsegments:
1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes
2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp

Which Firms Dominate the Xerostomia Therapeutics Market by Market Share and Revenue in 2025?
Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight* Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc

Which Regions Offer the Highest Growth Potential in the Xerostomia Therapeutics Market?
North America was the largest region in the xerostomia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15700

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert: Saumya Sahay: Americas +1 310-496-7795: Asia +44 7882 955267 & +91 8897263534: Europe +44 7882 955267: Email: saumyas@tbrc.info: The Business Research Company - www.thebusinessresearchcompany.com: Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.